The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations

Overview

Journal Front Oncol

Specialty Oncology

Date 2016 Sep 23

PMID 27656421

Citations 52

Authors

Yiyan Liu

Affiliations

Soon will be listed here.

Abstract

Unlike for most other malignancies, application of FDG PET/CT is limited for renal cell carcinoma (RCC), mainly due to physiological excretion of 18F-fluoro-2-deoxy-2-d-glucose (FDG) from the kidneys, which decreases contrast between renal lesions and normal tissue, and may obscure or mask the lesions of the kidneys. Published clinical observations were discordant regarding the role of FDG PET/CT in diagnosing and staging RCC, and FDG PET/CT is not recommended for this purpose based on current national and international guidelines. However, quantitative FDG PET/CT imaging may facilitate the prediction of the degree of tumor differentiation and allows for prognosis of the disease. FDG PET/CT has potency as an imaging biomarker to provide useful information about patient's survival. FDG PET/CT can be effectively used for postoperative surveillance and restaging with high sensitivity, specificity, and accuracy, as early diagnosis of recurrent/metastatic disease can drastically affect therapeutic decision and alter outcome of patients. FDG uptake is helpful for differentiating benign or bland emboli from tumor thrombosis in RCC patients. FDG PET/CT also has higher sensitivity and accuracy when compared with bone scan to detect RCC metastasis to the bone. FDG PET/CT can play a strong clinical role in the management of recurrent and metastatic RCC. In monitoring the efficacy of new target therapy such as tyrosine kinase inhibitors (TKIs) treatment for advanced RCC, FDG PET/CT has been increasingly used to assess the therapeutic efficacy, and change in FDG uptake is a strong indicator of biological response to TKI.

Citing Articles

Diagnostic and prognostic role of F-FDG PET/CT for sarcomatoid differentiation in renal cell carcinoma.

Na R, Chen Z, Liu Y, Chen Q, Yang Q, Qiu Y EJNMMI Res. 2025; 15(1):11.

PMID: 39971809 PMC: 11839549. DOI: 10.1186/s13550-025-01206-w.

The Utility of F-FDG PET/CT in Detecting Multiple Metastases in Papillary Renal Cell Carcinoma.

Oflas M, Simsek D, Kuyumcu S, Yilmaz Kiran M, Sanli Y Mol Imaging Radionucl Ther. 2025; 34(1):64-65.

PMID: 39918052 PMC: 11827522. DOI: 10.4274/mirt.galenos.2024.02259.

Gemcitabine-Loaded Microbeads for Transarterial Chemoembolization of Rabbit Renal Tumor Monitored by F-FDG Positron Emission Tomography/X-Ray Computed Tomography Imaging.

Zhang X, Li T, Tong J, Zhou M, Wang Z, Liu X Pharmaceutics. 2025; 16(12.

PMID: 39771587 PMC: 11678015. DOI: 10.3390/pharmaceutics16121609.

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials.

Li J, Luo P, Liu S, Fu M, Lin A, Liu Y Mater Today Bio. 2024; 27:101149.

PMID: 39100279 PMC: 11296058. DOI: 10.1016/j.mtbio.2024.101149.

HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma.

Bacigalupa Z, Arner E, Vlach L, Wolf M, Brown W, Krystofiak E J Clin Invest. 2024; 134(12).

PMID: 38941296 PMC: 11178540. DOI: 10.1172/JCI164249.

References

Kumar R, Shandal V, Shamim S, Jeph S, Singh H, Malhotra A . Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010; 31(10):844-50. DOI: 10.1097/MNM.0b013e32833d6882. View

Wang H, Ding H, Chen J, Chao C, Lu Y, Lin W . Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012; 12:464-74. PMC: 3483599. DOI: 10.1102/1470-7330.2012.0042. View

Lyrdal D, Boijsen M, Suurkula M, Lundstam S, Stierner U . Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009; 30(7):519-24. DOI: 10.1097/mnm.0b013e32832cc220. View

Nakhoda Z, Torigian D, Saboury B, Hofheinz F, Alavi A . Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies. Hell J Nucl Med. 2013; 16(1):19-24. DOI: 10.1967/s002449910067. View

Sharma P, Kumar R, Singh H, Jeph S, Patnecha M, Reddy R . Imaging thrombus in cancer patients with FDG PET-CT. Jpn J Radiol. 2011; 30(2):95-104. DOI: 10.1007/s11604-011-0016-9. View

Bertagna F, Motta F, Bertoli M, Bosio G, Fisogni S, Tardanico R . Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma. Nucl Med Rev Cent East Eur. 2013; 16(1):3-8. DOI: 10.5603/NMR.2013.0002. View

Kamel E, Jichlinski P, Prior J, Meuwly J, Delaloye J, Vaucher L . Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med. 2006; 47(11):1803-7. View

Ozulker T, Ozulker F, Ozbek E, Ozpacaci T . A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun. 2011; 32(4):265-72. DOI: 10.1097/MNM.0b013e3283442e3b. View

Ravina M, Hess S, Chauhan M, Jacob M, Alavi A . Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population. Clin Nucl Med. 2014; 39(9):767-71. DOI: 10.1097/RLU.0000000000000451. View

10.

Wu H, Yen R, Shen Y, Kao C, Lin C, Lee C . Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol. 2002; 128(9):503-6. DOI: 10.1007/s00432-002-0370-1. View

11.

Chen J, Appelbaum D, Kocherginsky M, Cowey C, Rathmell W, Mcdermott D . FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013; 2(4):545-52. PMC: 3799289. DOI: 10.1002/cam4.102. View

12.

Reinartz P, Wieres F, Schneider W, Schur A, Buell U . Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?. Eur J Nucl Med Mol Imaging. 2004; 31(11):1456-61. DOI: 10.1007/s00259-004-1593-y. View

13.

Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller S, Beyer T . Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004; 22(21):4357-68. DOI: 10.1200/JCO.2004.08.120. View

14.

Ferda J, Ferdova E, Hora M, Hes O, Finek J, Topolcan O . 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res. 2013; 33(6):2665-72. View

15.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L . Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011; 104(8):1256-61. PMC: 3078589. DOI: 10.1038/bjc.2011.103. View

16.

Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F . Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003; 30(9):1236-45. DOI: 10.1007/s00259-003-1211-4. View

17.

Rohren E, Turkington T, Coleman R . Clinical applications of PET in oncology. Radiology. 2004; 231(2):305-32. DOI: 10.1148/radiol.2312021185. View

18.

Ljungberg B, Hanbury D, Kuczyk M, Merseburger A, Mulders P, Patard J . Renal cell carcinoma guideline. Eur Urol. 2007; 51(6):1502-10. DOI: 10.1016/j.eururo.2007.03.035. View

19.

Liu Y, Ghesani N, Zuckier L . Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 2010; 40(4):294-315. DOI: 10.1053/j.semnuclmed.2010.02.002. View

20.

Jonasch E, Corn P, Pagliaro L, Warneke C, Johnson M, Tamboli P . Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2009; 116(1):57-65. PMC: 4636203. DOI: 10.1002/cncr.24685. View